HYDERABAD, India–(BUSINESS WIRE)–#AnalyticalDevelopment–Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated contract researchHYDERABAD, India–(BUSINESS WIRE)–#AnalyticalDevelopment–Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated contract research

Sai Life Sciences to Recruit 700+ Professionals in FY27

2026/02/20 17:15
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

HYDERABAD, India–(BUSINESS WIRE)–#AnalyticalDevelopment–Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated contract research, development and manufacturing organizations (CRDMOs), today announced plans to hire 700+ scientific, technical, and management professionals during 2026–27 as it scales capabilities to meet growing global demand for end-to-end drug discovery, development and manufacturing services.

The recruitment will span roles across medicinal chemistry, biology, DMPK, process and analytical development, formulation development, process engineering, technology transfer, quality, peptides, business development, program management, and manufacturing, among others.

A specific area of focus through this recruitment drive will be on attracting high-calibre scientists from leading institutions in India and globally, reflecting the increasing complexity of programs being entrusted to Sai Life Sciences and the higher scientific expectations placed on Indian CRDMOs by global innovator companies.

Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said: “We are at an inflection point for the Indian CRDMO industry. Global supply-chain rebalancing, the need for resilient development and manufacturing partners, and the rising sophistication of outsourced science are converging in India’s favour. Demand for high-quality, integrated partners is already visible, and this expansion is about preparing ourselves to serve that demand at scale — with the right infrastructure, strong digital and quality systems, and deep scientific capability.”

Krishna added, “For scientists, this is a genuinely exciting moment. They have the opportunity to work on globally relevant, high-impact programs while being based in India. We believe this phase of growth creates a compelling opportunity for Indian scientists anywhere in the world to consider building the next chapter of their careers here—without compromising on scientific rigor, exposure, or the quality of work.”

The new roles will support growing activity in areas such as complex small-molecule synthesis, high-throughput experimentation, data-enabled drug discovery, and late-stage CMC and commercial manufacturing scale-up.

As part of its talent strategy, Sai Life Sciences has launched a global alumni engagement platform and is strengthening learning, leadership development, and internal mobility programs to support long-term career growth.

Sai Life Sciences operates across India, the UK, and the US, serving global pharmaceutical and biotechnology companies. Its Manchester site focuses on process R&D, while its Boston Biology facility supports early discovery collaborations and client engagement. The majority of new roles will be based in Hyderabad, home to the company’s largest integrated R&D campus. With more than 3,400 scientists and professionals currently on board, the planned hiring reflects its continued growth and its expanding role as a global CRDMO partner.

About Sai Life Sciences

Sai Life Sciences is a full-service CRDMO working with innovator pharma and biotech companies globally to accelerate the discovery, development, and commercialization of small molecules. With operations across India, the UK, and the US, Sai Life Sciences offers scientific expertise, world-class infrastructure, and a culture of excellence focused on quality, safety, and sustainability. www.sailife.com

Contacts

For further information, contact:

Sriram Gopalakrishnan
Vice President, Corporate Communications
Sai Life Sciences  
Ph: +91 9121295355
sriram.g@sailife.com

Market Opportunity
Sharpe AI Logo
Sharpe AI Price(SAI)
$0.000965
$0.000965$0.000965
-2.03%
USD
Sharpe AI (SAI) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Walmart Recession Signal points to 'sharp economic downtown': Wall Street insider

Walmart Recession Signal points to 'sharp economic downtown': Wall Street insider

Jim Paulsen, a veteran economist and former chief investment strategist for the Leuthold Group (a Minneapolis-based investment research company), is known for operating
Share
Alternet2026/03/30 23:12
Trump’s Critical Warning: US Engages Iran’s New Regime in High-Stakes Talks, Threatens Strikes if Diplomacy Fails

Trump’s Critical Warning: US Engages Iran’s New Regime in High-Stakes Talks, Threatens Strikes if Diplomacy Fails

BitcoinWorld Trump’s Critical Warning: US Engages Iran’s New Regime in High-Stakes Talks, Threatens Strikes if Diplomacy Fails WASHINGTON, D.C. — March 15, 2025
Share
bitcoinworld2026/03/30 23:05
CME to launch Solana and XRP futures options on October 13, 2025

CME to launch Solana and XRP futures options on October 13, 2025

The post CME to launch Solana and XRP futures options on October 13, 2025 appeared on BitcoinEthereumNews.com. Key Takeaways CME Group will launch futures options for Solana (SOL) and XRP. The launch date is set for October 13, 2025. CME Group will launch futures options for Solana and XRP on October 13, 2025. The Chicago-based derivatives exchange will add the new crypto derivatives products to its existing digital asset offerings. The launch will provide institutional and retail traders with additional tools to hedge positions and speculate on price movements for both digital assets. The futures options will be based on CME’s existing Solana and XRP futures contracts. Trading will be conducted through CME Globex, the exchange’s electronic trading platform. Source: https://cryptobriefing.com/cme-solana-xrp-futures-options-launch-2025/
Share
BitcoinEthereumNews2025/09/18 01:07